S.A. Mason’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$443K Hold
1,900
– – 0.13% 146
2026
Q2
$403K Hold
1,900
– – 0.12% 153
2026
Q1
$372K Hold
1,900
– – 0.14% 142
2025
Q4
$330K Hold
1,900
– – 0.13% 152
2025
Q3
$362K Hold
1,900
– – 0.16% 132
2025
Q2
$341K Hold
1,900
– – 0.17% 133
2025
Q1
$321K Hold
1,900
– – 0.17% 132
2024
Q4
$287K Hold
1,900
– – 0.15% 137
2024
Q3
$295K Hold
1,900
– – 0.16% 138
2024
Q2
$260K Hold
1,900
– – 0.15% 139
2024
Q1
$253K Hold
1,900
– – 0.15% 139
2023
Q4
$262K Hold
1,900
– – 0.18% 131
2023
Q3
$232K Hold
1,900
– – 0.17% 140
2023
Q2
$269K Hold
1,900
– – 0.2% 130
2023
Q1
$269K Hold
1,900
– – 0.2% 130
2022
Q4
$297K Buy
1,900
+250
+15% +$35.9K 0.22% 117
2022
Q3
$202K Hold
1,650
– – 0.16% 142
2022
Q2
$219K Hold
1,650
– – 0.16% 144
2022
Q1
$226K Hold
1,650
– – 0.14% 151
2021
Q4
$285K Hold
1,650
– – 0.17% 134
2021
Q3
$240K Hold
1,650
– – 0.16% 147
2021
Q2
$218K Hold
1,650
– – 0.15% 152
2021
Q1
$212K Hold
1,650
– – 0.16% 150
2020
Q4
$197K Hold
1,650
– – 0.16% 143
2020
Q3
$189K Hold
1,650
– – 0.18% 133
2020
Q2
$188K Hold
1,650
– – 0.2% 126
2020
Q1
$132K Hold
1,650
– – 0.16% 134
2019
Q4
$176K Buy
+1,650
New +$172K 0.17% 133

Other funds holding DGX

S.A. Mason's DGX Position: Q3 2026 in Review

S.A. Mason held its Quest Diagnostics (DGX) position steady in Q3 2026 at 1,900 shares worth $443K. The position accounts for 0.13% of the portfolio, ranked #146.

S.A. Mason first reported a position in DGX in Q4 2019 and has held it in 28 quarters since. 266 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • S.A. Mason held 1,900 shares of Quest Diagnostics worth $443K as of Q3 2026.
  • S.A. Mason left its Quest Diagnostics share count unchanged in Q3 2026.
  • Quest Diagnostics made up 0.13% of S.A. Mason's portfolio in Q3 2026, its #146 holding.
  • S.A. Mason first reported a position in Quest Diagnostics in Q4 2019 and has held it in 28 quarters since.
  • 266 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on S.A. Mason's 13F filing for Q3 2026, filed 13 Oct 2026.